Cardiovascular Diagnostics, Bayer Corp. deal

CVDI will use its dry chemistry technology to develop a point-of-care test to monitor antithrombin (AT), a naturally occurring anticoagulant protein. Under the agreement, CVDI can access Bayer's trial of Thrombate III, which is being studied as a treatment for serious acquired coagulation problems, to help accumulate data for a 510(k) submission. ...